NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
The patients enrolled in IMMUNORARE will be adult patients with 5 rare cancers:
-Cohort 1: Peritoneal mesotheliomas (PM)
-Cohort 2: Gestational trophoblastic tumors (GTT)
-Cohort 3: B3 thymomas and thymic carcinomas (TET)
-Cohort 4: Anaplastic thyroid carcinomas (ATC)
-Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET)
Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.
1 total trials
Filter these 1 trials by phase, country, sponsor and more.